As of July 15, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here’s the latest list of major overbought players in this sector.

Progyny Inc (NASDAQ:PGNY)

• On July 13, Keybanc analyst Scott Schoenhaus maintained Progyny with an Overweight rating and raised the price target from $30 to $35. The company’s stock gained around 20% over the past month and has a 52-week high of $32.40.
• RSI Value: 83.2                                
• PGNY Price Action: Shares of Progyny rose 1.2% to close at $32.36 on Tuesday.
• Edge Stock Ratings: 92.51 Momentum score with Value at 58.37.

10X Genomics Inc (NASDAQ:TXG)

• On July 14, Canaccord Genuity analyst Kyle Mikson maintained 10x Genomics with a Buy and raised the price target from $32 to $50. The company’s stock gained around 42% over the past month and has a 52-week high of $45.82.
• RSI Value: 78.6
• TXG Price Action: Shares of 10X Genomics jumped 9.6% to close at $45.79 on Monday.

Privia Health Group Inc (NASDAQ:PRVA)

• On July 7, Privia Health said it will report second quarter results on Thursday, Aug. 6. The company’s stock gained around 22% over the past month and has a 52-week high of $28.30.
• RSI Value: 79.2                
• PRVA Price Action: Shares of Privia Health rose 0.5% to close at $28.03 on Tuesday.

Curious about other BZ Edge Rankings? Click here to discover how similar stocks measure up.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.